Read Time: 2 minutes
Frequent aspirin use is linked with lower ovarian cancer risk in individuals with multiple risk factors, according to a new study published in the Journal of Clinical Oncology.
“Ovarian cancer is the most fatal gynecologic cancer. Most known risk factors of ovarian cancer—such as family history, mutations in the BRCA 1 and 2 genes, and endometriosis—can’t be modified,” says Britton Trabert, PhD, MS, investigator in the Cancer Control and Population Sciences Program at Huntsman Cancer Institute and assistant professor of obstetrics and gynecology at the University of Utah School of Medicine. This new research holds promise because it shows an actionable step people at higher risk of ovarian cancer can take to reduce their chance of developing the disease.
“Daily, or almost daily, aspirin use was associated with a 13% reduction in ovarian cancer risk and we found that aspirin benefitted most subgroups. Importantly, this research provides further evidence that ovarian cancer chemoprevention with frequent aspirin use could benefit people in higher-risk subgroups.”
A 2018 study showed daily aspirin use is linked with reduced ovarian cancer rates. However, individual studies have not been able to look at whether aspirin would be beneficial to people at varying risk of disease.
Subgroups were defined by individual factors like endometriosis, obesity, a family history of breast or ovarian cancer, pregnancy, oral contraceptive use, tubal ligation, and by number of risk factors: none, one, and two or more.
“We pooled data from 17 studies, nine prospective cohort studies from the Ovarian Cancer Cohort Consortium, and eight case-control studies from the Ovarian Cancer Association Consortium that included more than 8,300 cases. This gave us a more detailed and accurate look than if we used published data.”
“Aspirin use has been linked with major adverse events, including internal bleeding and stroke. We wanted to evaluate whether aspirin could prevent ovarian cancer in people at higher risk. Since aspirin helped people who had two or more risk factors, we hope patients and clinicians can use this research to have an informed conversation when it comes to potential preventive measures. Individuals should consult their health care providers before beginning new medication in order to most appropriately balance any potential risks with the potential benefits.”
Trabert’s research focuses on identifying strategies for prevention or early detection of ovarian and endometrial cancers. Trabert earned a Department of Defense Investigator-Initiated Research Award related to her work with aspirin use and lower ovarian cancer rates.
The study was supported by the U.S. Department of Defense Ovarian Cancer Research Program (W81XWH-19-1-0346).
Media Contact
Heather Simonsen
Public Affairs Senior Manager
Huntsman Cancer Institute
801 581-3194
public.affairs@hci.utah.edu
About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the University of Utah is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, Idaho, Montana, Nevada, and Wyoming. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing and prevention through scientific breakthroughs and cutting-edge technology to advance cancer treatments of the future beyond the standard of care today. We have more than 300 open clinical trials and 250 research teams studying cancer. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient’s unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.